KEY DETAILS
The Sun reports that naltrexone is licensed in the UK but is not currently available on the NHS for alcohol addiction.
According to the New York Post, the real retatrutide is still undergoing clinical trials in the US and has not reached the market.
The Guardian reports that Eli Lilly, maker of Zepbound and Mounjaro, was among the sponsors of Vogue World Milano.
The Star reports an observational review of 10 studies found no clearly detectable rise in complications after GLP-1 use around conception.
Times Now News reports on a video, first shared in September 2025, of Japanese influencer Yuipis injecting Mounjaro right after buying it.
The Sun reported on October 30 that naltrexone, the opioid blocker it calls the 'Ozempic for alcoholics', is licensed in the UK but is not currently available on the NHS for alcohol addiction. There is a good deal more to get through after that. According to The Star, which published its report on the same date, an observational review of 10 studies found no clearly detectable rise in complications among women exposed to GLP-1 drugs around conception.
The Sun builds its story around Katie Lain, who says she is in recovery from alcohol addiction. According to The Sun, she began taking naltrexone in July 2017 under the Sinclair Method, which pairs the drug, taken before drinking, with therapy and personal development. The Sun says naltrexone works by blocking the brain's opioid receptors, and the paper compares this to the way Ozempic or Mounjaro numbs food cravings. The Sun also reports that a month's supply costs about £100, and that because the drug is classed as off-label for alcohol addiction, it has to be bought privately. The next story concerns a very different kind of drug.
The New York Post reports that Megan Hancocks, 32, developed acute liver failure within days of injecting a black-market peptide labelled as retatrutide, as she told Australia's ABC News. Her account is a hard one to read. According to the Post, she spent about a month in hospital and recovered enough to avoid a liver transplant. The Post also reports that the FDA has issued warnings about retatrutide and all other unapproved, compounded GLP-1 medications. The next story moves from medicine to fashion.
The Guardian reports that eating disorder advocates spoke out against the association between the fashion show and the company that makes Zepbound and Mounjaro. According to The Guardian, an Eli Lilly spokesperson said the company works with cultural platforms like Vogue because that is where conversations about bodies and health take place. The Guardian article goes on to argue that body positivity has all but vanished within mainstream visual culture while much of its social training lingers. The next item is a research story.
According to The Star, the review was carried out by researchers at City St George's, University of London, and included more than two million women, of whom more than 8,000 were exposed to the drugs around conception. The Star reports that the findings are published in the Cell Press journal Med. This one needs its caveats kept in view. The Star quotes Professor Asma Khalil as saying the findings are reassuring but do not establish that these medications are safe during pregnancy, and that current recommendations to stop GLP-1 drugs before a planned pregnancy should continue to be followed. The last story comes from social media.
Times Now News reports that the video was first shared by a doctor in September 2025, with a warning against injecting Mounjaro at the clinic entrance right after buying it. According to Times Now News, the clip resurfaced in January 2026 after the influencer reacted to it herself. The outlet reports that she stands 170 cm tall and weighs 47 kg, which it calculates as a BMI of about 16.3. Times Now News also reports that Japan's official Mounjaro prescribing information states that safety and effectiveness have not been established in people with a BMI below 23 kg/m².
Each of these stories carries more detail than fits in a short edition. The full articles are available at The Sun, the New York Post, The Guardian, The Star and Times Now News, all linked in this edition.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.